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Introduction: Radiotherapy has proven to be an effective treatment 
when used alone or with other therapies. However, underuse of radio-
therapy has been observed in various studies. The objective of this 
investigation was to assess the use of radiotherapy as initial treatment 
for lung cancer in a southern region of Europe.
Methods: A systematic review of lung cancer treatment guidelines 
and observational studies was performed to estimate expected radia-
tion rates and the associated survival outcomes. We then reviewed 
the clinical and treatment records of all patients undergoing radio-
therapy for lung cancer during 2007 in all the 12 public hospitals in 
Andalusia with radiotherapy facilities. Data were grouped accord-
ing to type of hospital, patient, treatment characteristics, histological 
type, and tumor stage.
Results: In 2007, of the 3051 patients estimated to be diagnosed 
with lung cancer, 610 were treated with initial radiotherapy with an 
overall radiation rate of 20%, which significantly differed among 
provinces (range, 8.5%–25.6%, p < 0.001). Given the expected 
 radiation rate of 1383 patients, 773 more patients of lung cancer 
(25%) should have been treated. According to the literature, the 
maximum increased survival attributable to the use of radiotherapy 
in patients diagnosed with non–small-cell lung cancer ranges from 
1.8 to 14.1 months. The underuse estimated in the region would 
 correspond to a loss of more than 3000 months in survival time.
Conclusions: The observed underuse of radiotherapy in lung cancer 
in our region should be a matter of concern, given its negative and 
measurable impact on the survival of the patients.
Key Words: Lung cancer, Variability, Underuse, Survival, 
Radiotherapy.
(J Thorac Oncol. 2013;8: 62–67)
Lung cancer remains a major health problem in our society.1 In Spain, 20,000 new cases are diagnosed every year and 
18,000 people die of the disease; it is the first cause of death 
by cancer in men and the third, after breast and colorectal 
cancer, in women. The incidence in women (almost sixfold 
lower than in men) has begun to increase in Spain, as in other 
Western societies.2,3
Non–small-cell lung cancer (NSCLC) represents 80% 
of lung cancer cases and its clinical management depends to 
a high degree on the tumor burden at the time of diagnosis, 
as measured by the stage classification system.4 According 
to clinical evidence accumulated over the past few decades, 
optimal outcomes are obtained if tumors are treated in early 
stages, when surgery is more feasible. Surgery at the time of 
diagnosis is possible in 15% to 25% of patients, usually in 
those with stages I or II and sometimes with IIIA.1,5 When 
surgery is not possible (e.g., in patients with stage IIIB, and 
sometimes with stages II and IIIA), there is a strong consensus 
that different combinations of chemotherapy (CT) and radio-
therapy (RT) should be administered in a multidisciplinary 
approach.5 In most patients with stage IV, the recommended 
treatment is CT, which is associated with RT for palliative and 
symptom control purposes. At the time of diagnosis, 30% to 
50% of NSCLC patients have stage III disease and 40% have 
stage IV.6,7
The standard approach in small-cell lung cancer (SCLC) 
is combined CT and RT, if the disease is limited, which is gen-
erally followed by prophylactic cranial irradiation. In cases of 
extended disease, CT is the therapy of choice, reserving RT 
for palliative treatment and symptom control.6,7
RT alone or in combination has proven to be effective 
in lung cancer1,8 but may be underused. Studies of the 
radiation rate (number of patients treated in proportion to total 
diagnosed cases) are used to examine whether adequate use 
is made of this important treatment modality and to identify 
patient groups that may not be obtaining this potential benefit. 
Two methodologies are used to estimate the RT in lung 
cancer: epidemiological and evidence-based estimations,9 
and estimations based on benchmarking criteria.10 It has been 
calculated that 45% to 55% of patients can benefit from RT in 
their initial treatment and a further 15% during the course of 
the disease. By following this model, it is possible to determine 
the amount of benefit that RT may provide as a function of 
the stage and histological type (mainly NSCLC or SCLC) of 
lung cancer. Barbera et al.11 reported that the potential median 
survival benefit of RT ranges from 2.2 months in advanced 
stages of NSCLC and SCLC to 14.1 months in early stages 
of nonoperable NSCLC. Reports on clinical practice have 
revealed that the use of RT in lung cancer is less frequent than 
could be expected.10,12–14 Our group assessed the radiation 
rate for lung cancer in Andalusia in 2004 (Variability and 
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Adequacy of the use of Radiotherapy in Andalusia [VARA] I 
study) and 2007 (VARA II study)15,16 and found that initial RT 
was received by 20% of lung cancer patients, which indicated 
that it was not administered to 25% to 35% of eligible patients. 
The objective of the present study was to quantify the RT 
underuse in our setting, based on clinical data and a review of 
the most recent literature and clinical guidelines, and evaluate 
its impact on survival.
Andalusia has a surface area of 87,597 km2 and 7.8 
million inhabitants; approximately half (45.6%) of the popu-
lation lives within a 20-km radius around the eight cities in 
the region. The regional public health system provides uni-
versal free coverage, whereas 10% of the total care is deliv-
ered in private health care facilities. Most of the health care 
is provided in the 34 public hospitals, of which 12 possess RT 
departments. Each province has at least one public RT facility. 
Data were collected from public and private centers.
MATERIALS AND METHODS 
In 2007, a retrospective longitudinal study was con-
ducted in Andalusian in all the 12 public hospitals that offered 
RT treatments.
Data on all patients with a diagnosis of lung cancer (any 
histological type and stage) who received initial treatment 
with lung RT were gathered from the hospital cancer regis-
tries, hospital discharge information systems (minimum basic 
data set), and clinical management computer systems linked 
to the RT equipment (e.g., Varis, Lantis, and Impac networks). 
Population data were obtained from the Spanish National 
Statistics Institute (http://www.ine.es).17 Cases included in 
the study were checked against extrapolations from the pop-
ulation-based cancer registry in one province of the region 
(Granada) and against national estimates. Distributions by his-
tological type and stage were extrapolated from data from the 
Population Cancer Registry of Granada.18 Trained researchers, 
supervised by the staff at each center, obtained patient data 
from the clinical records and individual treatment records of 
patients who received RT as initial treatment.
Study variables included characteristics of the hospi-
tal (province, megavoltage units, and professionals), patient 
(age, sex, histological type, performance status with Eastern 
Cooperative Oncology Group scale or Karnofsky scale, 
weight loss, and comorbidity), and treatment (medical indica-
tion, therapeutic intent, total doses, fractions, nodal irradia-
tion, delay, days of treatment, planning with two-dimensional 
or three-dimensional, electron linear accelerator or cobalt 60 
treatment, and adverse effects). The radiation rate was calcu-
lated for each hospital and for the population that it covered. 
The number of patients on whom RT could be performed was 
expressed as the percentage of cases by stage (for NSCLC) or 
by their limited or extended nature (for SCLC).
We reviewed the literature to date on the role of RT in lung 
cancer and estimated its benefit in each clinical situation based 
on the studies by Tyldesley et al.,9 Barbera et al.,11 and Delaney 
et al.19 We studied the most recent clinical practice guidelines 
on lung cancer and reviewed the literature over the past 10 years 
to ensure that the evidence-based estimate models were up to 
date. We used the following search algorithm in MEDLINE: 
(Health Planning[Mesh]); (radiotherapy[subheading]; radio-
therapy [all fields]; radiotherapy[MeSH terms]); (lung[MeSH 
terms]; lung [all fields]). The focus of our investigation was the 
influence of RT as an initial postdiagnosis treatment on lung 
cancer survival outcomes.
Statistical Analysis
A descriptive analysis was performed. The χ2 test was 
used to study the independence of qualitative variables, apply-
ing Fisher’s exact test for binary variables. Pearson’s corre-
lation coefficient (or the nonparametric Kendall’s tau-b or 
Spearman’s rho) and linear regression analysis were used to 
study relationships among quantitative variables. Two-sided p 
values less than 0.05 were considered significant. SPSS ver-
sion 12.0 (SPSS, Chicago, IL) was used for statistical analyses.
Ethical Considerations
This was a prospective study with no diagnostic or 
therapeutic implications. It was approved by the Andalusian 
Ethics Committee for Clinical Trials.
RESULTS
According to estimates based on data from the 
Population Cancer Registry of Granada, there were 3051 
incident cases of lung cancer, during the study period, in 
the population of Andalusia. Of these, we obtained data on 
610 patients who received RT as initial treatment. Data from 
clinical records on the histological type, clinical stage, and 
radiotherapy treatment could be collected in the majority of 
patients (88%, 76%, and 100%, respectively). Missing data 
were related to performance status (47%), comorbidity (26%), 
weight loss (44%), and toxicity (77%).
Of the 610 irradiated patients, 58% underwent RT with 
radical intent (RT adjuvant to surgery in 8% of these) and 42% 
with palliative intent. The radiation rate was 20% (Table 1). 
Significant differences in radiation rates were observed among 
the eight provinces of Andalusia, ranging from 8.5% to 25.6% 
(p < 0.001).
Table 2 shows the distribution by stage and histology of 
the 3051 expected cases, with indication of initial RT for lung 
cancer. Among the NSCLC cases, 62% were with stage III 
TABLE 1.  Overall and Lung Cancer Radiation Rates by Province
Province LC Cases RT for LC LC RT Rate (%)a
1 244 21 9
2 458 54 12
3 305 70 23
4 336 87 26
5 183 48 26
6 244 48 20
7 580 132 23
8 701 150 21
Total 3051 610 20
aSignificant difference p < 0.001
RT, radiotherapy; LC, lung cancer.
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and 26% with stage IV. According to recommended radiation 
rates,9,11 1383 of these patients were expected to receive RT 
(1132 [82%] with NSCLC and 251 [18%] with SCLC), that is, 
37% of NSCLC patients in stage II, 77% of those in stage III, 
and 35% of those in stage IV, and 34% of SCLC patients with 
limited disease. Table 2 also gives the distribution of the 610 
patients who actually received initial RT (excluding prophylactic 
cranial irradiation) by therapeutic intent (radical or palliative). 
According to these results, there was a statistically significant 
difference between the theoretical number of lung cancer cases 
for whom initial RT was indicated and the actual number who 
received this treatment. Specifically, an additional 638 NSCLC 
patients should have received RT during the study period, pre-
dominantly patients with stages III and IV of NSCLC.
Of the 33 clinical practice guidelines consulted, seven 
were initially selected as being sufficiently comprehensive, 
and information from three of these6,7,21 was finally used in 
our update of recommendations based on their high Appraisal 
of Guidelines Research and Evaluation (AGREE) scores.20 
Of the 46 studies yielded by our search of the literature, 18 
were selected for full-length reading mostly related to differ-
ences in radiation rates and patterns of care in radiotherapy for 
lung cancer patients. Table 3 lists the indications for initial RT 
by stage and reports the clinical benefit (months of survival 
because of RT) described in the reviewed studies. Survival 
gains attributed to exclusive RT range from 1.8 months in 
patients with advanced disease and poor general health status 
to 14 to 18 months in NSCLC patients who are inoperable 
because of medical problems.
According to the difference between recommended 
and observed radiation rates in our population, the failure 
to administer RT to the 773 lung cancer patients who may 
have benefited represents a total survival loss of 3038 to 3553 
months (253–296 years).
DISCUSSION
The radiation rate obtained in our study was 20%, which 
can be considered very low. The role of RT in the treatment 
of lung cancer is adequately established in clinical practice 
guidelines.6,7,21 Using a benchmark approach, Barbera et 
al.10 reported that initial RT was indicated in 41.3% of lung 
cancer cases, and similar conclusions were reached by other 
authors using different study methods.14,19 The Queen’s Cancer 
Research Institute estimated the appropriate radiotherapy rate 
for lung cancer patients to be as high as 61%,9 as noted by 
the European Estro Quarts project.22 The percentage of lung 
cancer patients eligible for RT includes those with resectable 
but nonoperable NSCLC in stages I and II, among whom RT 
has achieved 5-year survival rates of 22% to 37%.23–25 It also 
includes the much more numerous group of patients with 
advanced disease (stages IIIa–b) but preserved general health 
status (performance status 0–1), who receive RT alone or with 
CT.26–32 Finally, RT with palliative intent has proven benefi-
cial in comparison to support measures alone.33–35 Small-cell 
tumors can also benefit from treatment with local RT and with 
whole-brain radiation, which has not been considered here.36
According to the literature,9,11 an additional 773 lung 
cancer patients (25%) should have been treated. Authors 
TABLE 2.  Distribution and Comparison of Expected and Observed Cases of Radiotherapy-Related Lung Cancer by Histology 
and Stage
NSCLC SCLC
Stage
Expected Cases Observed Cases Comparison 
Between 
Observed and 
Expected  
Cases of  
RT-Related LC
Stage
Expected Cases Observed Cases Comparison 
Between 
Observed 
and Expected 
Cases of  
RT-Related LC
(n = 2440; 80%) (n = 494; 81%) (n = 611; 20%) (n = 116; 19%) 
Casesa RTb n (%) n (%) Total (%) Difference Casesa RTb n (%) n (%) Total (%) Difference
n (%) n (%) radical palliative n (%) n (%) radical palliative
I 456 123 17 4 21 −102
(19) (27) (6.2) (2) (4.2)
II 219 81 33 8 41 −40 Limited 244 208 82 — 82 −126
(9) (37) (12) (3.7) (8.3) (40) (34) (71) (71)
III 741 570 179 125 304 −266
(30) (77) (66) (57.6)  (61.5)
IV 1024 358 45 83 128 −230 Extended 367 43 — 34 34 −9
(42) (35) (16) (37.3) (26) (60) (7) (29) (29)
2440 1132 274 220 494 −638 611 251 82 34 116 −135
(46.4) (55.4) (44.6) (100) (41) (71) (29) (100)
VARA II.
aStage distribution following 18.
bPercentage of initial radiotherapy following 9 and 10.
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; RT, radiotherapy; LC, lung cancer.
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investigating the true rate of RT use in lung cancer have 
expressed concern about the differences in the theoretical rate.13 
An important discrepancy between these rates was also found 
in the present survey, although the radiation rate (20%) was 5% 
higher than was recorded in a similar study of our region 3 years 
earlier (relative increase of 17%). Major variations among the 
eight provinces were observed, as in the previous report, which 
is consistent with geographic variations described within other 
countries.37,38 Although global outcomes remain poor in lung 
cancer, with a 5-year survival of approximately 15%,39 the 20% 
radiation rate found in our study represents an underuse of RT, 
which needs to be addressed.
Analysis of RT underuse by NSCLC stage and by the 
local or disseminated status of SCLC revealed significant dif-
ferences between clinical practice guidelines and the different 
lung cancer treatment protocols in our setting. According to our 
data, the highest underuse rate is among patients with stages 
III and IV, who could obtain an important benefit from RT,26–35 
suggesting that the main underuse lies in its application with 
palliative intent. It is well documented that radiotherapy signif-
icantly improves the quality of life of patients.40,41 According to 
the published data,42,43 a palliative effect (improvement in out-
come and symptom relief) can be achieved in 60% to 80% of 
patients with clinical superior vena cava syndrome, and other 
symptoms (e.g., hemoptysis, chest pain, and anorexia) disap-
peared in more than 50% of cases. Endobronchial radiation 
has been reported to offer an 82% improvement in dyspnea, 
89% improvement in hemoptysis, and 92% improvement in 
postobstructive pneumonia. Barbera et al.11 showed that the 
average duration of symptom control gained per case, when 
treated with palliative intent, is 3.9 months in SCLC and 2.9 
months in NSCLC. Hence, palliative RT has an important role 
in lung cancer and offers benefits to the patients.
Given the population-based retrospective design of our 
study, the difficulty of achieving a full coverage of cancer-
incident cases, and the uncertain reliability of data sources 
based on clinical records, we may have underestimated the 
total number of patients receiving RT for lung cancer, although 
it is consistent with data gathered in the VARA-I study 3 years 
earlier. A further study limitation is the lack of an evalua-
tion of the contribution of different components of multidis-
ciplinary treatment to the outcome. This issue is especially 
critical in analyses of the clinical stages of the disease, given 
the variability in the effectiveness of different treatments at 
distinct stages. The net survival benefit of RT assumed in our 
study is based on our update of the relevant literature.44–46 In 
addition, as is often the case with large databases on public 
health, there is little detailed clinical information on individ-
ual patients in the study or on their comorbidities. This means 
that we are unable to determine whether the low RT rate in 
stage III NSCLC is because of a large number of patients with 
IIIb disease, a high rate of neoadjuvant chemotherapy plus 
surgery, or high frequency of severe chronic obstructive pul-
monary or heart disease that precludes radiotherapy. However, 
it is unlikely that these factors could explain the large differ-
ence found between expected and observed cases. The low RT 
rate may also be attributable to a failure to refer the patients 
to radiation oncology. Stevens et al.13 found that some of the 
patients in their study were not referred to radiation oncol-
ogy, although the reasons for this were not clearly understood. 
The lack of a multidisciplinary team that includes a radiation 
oncologist may in part explain this underuse. In addition, the 
majority of studies on trends in lung cancer management have 
detected an increased use of chemotherapy.47,48 Finally, the 
Andalusian public health system provides universal free cov-
erage, therefore, economic differences in populations can be 
ruled out as a possible cause of reduced accessibility.
Variations in medical practice constitute a well-
consolidated research approach. Possible explanations of 
variations were compiled and classified by Wennberg and 
Gittelsohn.49,50 The underuse observed in the present study may 
be partly explained by a deficit in resources, compromising 
accessibility to the therapy. In the region as a whole, there was 
a mean of 4.2 megavoltage units per million inhabitants, which 
is low in comparison to the European Union average,22 and the 
median indication-to-treatment interval was approximately 41 
days, which seems a reasonable delay, although this interval 
significantly differed among hospitals.
TABLE 3.  Indication for Initial Radiotherapy Treatment in Lung Cancer, Number of Cases, Potential Survival Benefit and 
Radiotherapy Benefit not Received
NSCLC/Stage RT Type Indicationa Percentage of  
Cases in Stage
Benefit  
(mo)
Source Difference  
R/Tb
Months of Benefit  
not Received
I/II inoperable RTr 1b 20 ± 1.8 14/18 23, 24, 25 −80 1120/1440
I/II /IIIa postsurgery RTr 2c 8 4.8 26, 27 −41 196.8
IIIa potentially resectable RTr+CT 1b 75 ± 10 5–8 28, 29, 30 −66.5 332/532
IIIb PS 0–1 RTr+CT 1a 5–8 30, 31, 32 −98.25 491/786
IIIb PS>2, weight loss RTp 1a 1.8 33, 34 , 35 −98.25 176.8
IV RTp 1a 35 ± 7 1.8 21 −230 419.4
SCLC limited RTc. 1a 34 ± 3 2.4 36 −126 302.4
Total Total
−740 3038.4/3553.4
aLevel of evidence and grade of recommendation (Evidence-based medicine according to reference 7) 
bDifference between real and theoretical cases by stage, performance status, and indication for surgery.
RT, radiotherapy; RTr, radical radiotherapy; RTp, palliative radiotherapy; RTc, radiotherapy for consolidation; CT, chemctherapy; PS, performance status; NSCLC, non–small-cell 
lung cancer; SCLC, small-cell lung cancer.
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The potential influence of socioeconomic factors51 was 
not addressed in this study. Variations in the application of RT 
in lung cancer may also be because of differences in clinical 
decision making, as reported by other authors.52,53 Interestingly, 
our review of clinical trials over the past decade showed that 
the standard treatment control arm in most of them does not 
include RT.20,54 A parallel investigation in our region carried 
out by the Health Technology Agency over the same period 
reached the unexpected conclusion that the higher number 
of patients receiving initial CT than RT for lung cancer was 
related to easier access to cytostatic treatments and greater 
discretion in their use by the attending physician,55 supporting 
the hypothesis that the clinical pattern of care makes a partial 
contribution to RT underuse.
In summary, there seems to be a suboptimal use of RT 
in lung cancer patients in our region. The underuse during 
the year under study may have been responsible for an over-
all loss of more than 700 patients in our region, who did not 
receive the clinical benefits of RT treatment with either radical 
or palliative intent. It is difficult to explain why a treatment 
of proven effectiveness is withheld from patients with a dis-
ease that has a very poor prognosis, but it clearly indicates 
the need for action to improve accessibility to RT resources. 
Furthermore, reasonable options to increase the proper use of 
RT in our region would include a greater involvement of radia-
tion oncologists in multidisciplinary tumor boards to enhance 
appropriate evidence-based decision making.
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